Search

Your search keyword '"Sellner L"' showing total 146 results

Search Constraints

Start Over You searched for: Author "Sellner L" Remove constraint Author: "Sellner L"
146 results on '"Sellner L"'

Search Results

1. EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL)

3. Dissection of CD20 regulation in lymphoma using RNAi

12. Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma : A survey of the EBMT lymphoma working party

13. THE LANDSCAPE OF DRUG PERTURBATION EFFECTS IN LEUKEMIA AND LYMPHOMA

14. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

16. A Phase I Study of CD19‐targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B‐cell Lymphoma.

17. Distinct phenotype of CD19-specific CAR T cells generated from healthy donor vs. patient lymphocytes using either IL-7/IL-15 or IL-2

18. ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data

19. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

20. DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE DISORDERS

21. GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses

23. T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells

24. SYSTEMATIC DRUG SENSITIVITY SCREENING IN LYMPHOID MALIGNANCIES IDENTIFIES VULNERABILITIES OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH HIGH RISK ABERRATIONS

27. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling

32. New techniques for evaluating lung immunology and immunopathology

36. Calibrated CAR Signaling Enables Low-Dose Therapy in Large B-Cell Lymphoma.

37. Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia.

38. HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma.

39. Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers.

41. Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies.

42. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4 + T cells in chronic lymphocytic leukemia.

43. Dual Effects of Cyclooxygenase Inhibitors in Combination With CD19.CAR-T Cell Immunotherapy.

44. An Endoplasmic Reticulum Specific Pro-amplifier of Reactive Oxygen Species in Cancer Cells.

45. Changes in treatment landscape of relapsed or refractory multiple myeloma and their association with mortality: Insights from German claims database.

46. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.

47. Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells.

49. Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells.

50. Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.

Catalog

Books, media, physical & digital resources